%0 Journal Article %A Hisato Takagi %A Toshiki Kuno %A Yujiro Yokoyama %A Hiroki Ueyama %A Takuya Matsushiro %A Yosuke Hari %A Tomo Ando %T Higher Temperature, Pressure, and Ultraviolet Are Associated with Less COVID-19 Prevalence – Meta-Regression of Japanese Prefectural Data %D 2020 %R 10.1101/2020.05.09.20096321 %J medRxiv %P 2020.05.09.20096321 %X A recent study from China suggests that high temperature and ultraviolet (UV) radiation cannot decrease the epidemics of Coronavirus disease 2019 (COVID-19). To determine whether COVID-19 prevalence is modulated by meteorological conditions, meta-regression of Japanese prefectural data was herein conducted. We extracted integrated number of patients testing positive for COVID-19 in each Japanese prefecture on 18 May 2020, population per 1-km2 inhabitable area in the prefecture in 2020, and monthly meteorological conditions at each prefectural capital city for 4 months (from January to April 2020). We averaged or cumulated the monthly data for the 4 months. To adjust for prefectural population density, we defined the COVID-19 prevalence as the integrated number of patients testing positive divided by the population per 100-km2 inhabitable area. Random-effects meta-regression was performed. A slope of the meta-regression line was significantly negative for mean air temperature (coefficient, −0.134; P = 0.019), mean sea level air pressure (−0.351; P = 0.001), and mean daily maximum UV index (−0.908; P = 0.012), which indicated that COVID-19 prevalence decreased significantly as air temperature, air pressure, and UV index increased. In conclusion, higher temperature, pressure, and UV may be associated with less COVID-19 prevalence, which should be confirmed by further epidemiological investigations taking other risk and protective factors of COVID-19 into account.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. %U https://www.medrxiv.org/content/medrxiv/early/2020/05/21/2020.05.09.20096321.full.pdf